Results of Anaconda Biomed's ANAIS study published in the American Journal of Neuroradiology
In a significant development for the neurovascular field, Anaconda Biomed, a leading company in the design and production of intravascular devices, has appointed a new CEO. However, when it comes to the ATHENA clinical trial using their ANA funnel catheter for acute ischemic stroke, the latest findings and developments remain elusive.
A recent search of various sources, including company reports, scientific blog summaries, and clinical data collections, has revealed no information specifically on the ATHENA trial or Anaconda Biomed's ANA funnel catheter. No press releases, clinical trial registries, or medical journal excerpts mentioning ATHENA or the ANA funnel catheter were found.
The ANA5 catheter, a new funnel catheter designed for neurovascular procedures, was evaluated in the ANAIS study, published in the American Journal of Neuroradiology. The study, conducted across three centers in Spain, had a total of 43 patients enrolled. The results showed that when the ANA device was deployed in the ICA C2-C3 segment and continuous aspiration was applied, first pass effect (FPE) was achieved in 83% of the cases, with successful reperfusion within three passes in 100% of this population.
Despite the promising results from the ANAIS study, no detailed updates on the ongoing ATHENA clinical trial are available. The high rates of FPE observed in the ANAIS study are being implemented in the ATHENA trial, the first randomised stroke trial to include FPE as a primary outcome measure.
Anaconda Biomed's Chief Medical Officer, Hendrik Lambert, expressed gratitude to the investigators, centers, and patients who contributed to the ANAIS study. He also noted that no severe device-related adverse events or symptomatic intracranial hemorrhages were observed at 24 hours.
The ANA5 catheter's large lumen matches the diameter of the target artery, potentially enhancing clot removal during thrombectomy procedures. The catheter also features a radiopaque, self-expanding funnel covered with a continuous sealing coating. Anaconda Biomed has received CE Mark for the ANA5 Funnel Catheter.
For the most up-to-date clinical trial results and status, it is recommended to consult clinical trial registries such as ClinicalTrials.gov, published articles in stroke/neurovascular journals, official company press releases or medical conference abstracts from Anaconda Biomed, and by contacting the trial investigators or the company directly.
- Despite the pending results of the ATHENA clinical trial, the medical-condition of acute ischemic stroke has been shown to have a potential treatment with the ANA5 catheter, a health-and-wellness device designed for neurovascular procedures, as demonstrated in the ANAIS study.
- In the absence of specific information related to the ATHENA trial or Anaconda Biomed's ANA funnel catheter, it is crucial to monitor scientific journals, clinical trial registries, and company announcements for updates on the development and application of neuralogical-disorders treatments, such as the ANA5 catheter for acute ischemic stroke.
